ER/PR-positive breast cancers can be treated by hormonal therapies such as tamoxifen or aromatase inhibitors, while HER2-positive breast cancers respond well to targeted therapies like trastuzumab (Herceptin) [5]. Here, ESR1 is linked to breast carcinoma.